A companion to Cancer & the Fire

The Warburg
Lineage.

The fun one — history, not advice. It follows a single idea across almost a century: that cancer is, in some deep way, a problem of metabolism. The idea won a Nobel Prize, overreached, was buried for decades, came roaring back, and has now produced actual cancer drugs. A story about how science corrects itself — and a man who was right about the machinery, too strong about the cause, and prophetic all the same.

Scroll to begin
One idea, almost a century

Remembered for the wrong thing.

Otto Warburg was one of the great biochemists of the twentieth century, and he's remembered — usually — for the wrong thing. Ask most people what he's famous for and they'll say cancer. But the Nobel Prize on his shelf was for something else entirely, and clearing up the confusion opens the whole story.

Right about the machinery, too strong about the cause, and prophetic about metabolism mattering at all.
A note on what this is. A history-and-mechanism piece, not medical advice, and nothing here is a treatment claim. The one place it touches real medicine — the modern cancer drugs at the end — is described as what it is: prescription oncology, given by mutation, under specialist care.
Walk the century

From a Nobel to a prescription pad.

One idea — cancer as a metabolic problem — across almost a hundred years. Click along the line, or step through it, and watch it rise, fall, and rise again.

The lineage, 1931 → today
Tap a point on the timeline to see what happened — and how the idea kept turning.
A guided walk through the story below — every step is set out in full underneath.
1931 · what he actually won

The respiratory enzyme.

Warburg took the 1931 Nobel Prize in Physiology or Medicine "for his discovery of the nature and mode of action of the respiratory enzyme" — the Atmungsferment, what we now call cytochrome c oxidase: the enzyme at the very end of the electron transport chain, the one that finally hands the spent electrons to oxygen. His prize was for working out how a cell uses oxygen to burn fuel — the exact machinery the Two Fuels chapter describes.

The work was as elegant as it was important. He built the tools — the Warburg manometer, to measure how fast a slice of living tissue consumed oxygen — and pulled off a beautiful experiment: knowing the enzyme was poisoned by carbon monoxide and that light reversed the poisoning, he measured which colours of light broke the poison's grip and reconstructed the enzyme's identity from that alone. Note carefully: this Nobel had nothing to do with the "Warburg effect" most people attach to his name.

1956 · the overreach

A theory too strong.

Separately, in the 1920s, Warburg noticed cancer cells ferment glucose to lactate at a furious rate even when oxygen is freely available — "aerobic glycolysis," now the Warburg effect. Normal cells only ferment when starved of oxygen; cancer cells do it in the middle of plenty. From this he built a sweeping claim, stated most famously in his 1956 paper "On the origin of cancer cells": that the prime cause of cancer is damaged respiration.[1]

That was too strong. When the genetic revolution arrived — oncogenes, tumour-suppressors, DNA as the seat of cancer — Warburg's metabolic theory was sidelined for decades as a quaint dead end. The effect was real; the cause he hung on it was not accepted. For a long stretch, saying "cancer is a metabolic disease" marked you as behind the times.

2009 · the resurrection

Why proliferating cells ferment.

Two things brought the idea back. First, the machinery under Warburg's enzyme was completed by others — Krebs (Warburg's own assistant) with the citric-acid cycle, Mitchell with the chemiosmotic theory. Second, and more importantly, the Warburg effect got a better explanation. In a landmark 2009 review, Matthew Vander Heiden, Lewis Cantley and Craig Thompson reframed it: a fast-dividing cell ferments not because its mitochondria are broken, but because fermentation is a fast way to grab carbon building-blocks for new cell membranes, DNA and proteins.[2]

The tumour isn't a broken engine limping on fermentation; it's a factory, diverting fuel to construction. That turned the Warburg effect from a curiosity into a logic — and quietly overturned Warburg's own premise: most cancers, it turns out, have working mitochondria and use them.

2018 · the insulin bridge

Cantley, PI3K, and a ketogenic experiment.

One of those three authors is the bridge from Warburg straight to the insulin thesis of this whole series. Lewis Cantley's landmark discovery, in the 1980s, was PI3K — the enzyme that carries the signal from insulin and growth factors into the cell's decisions about growth. When insulin knocks, PI3K answers. Its gene, PIK3CA, is among the most frequently mutated in all of human cancer. Cantley, in effect, found the molecular wire connecting the hormone at the centre of this series to the growth behaviour of tumours.

In 2018 his group showed why some targeted cancer drugs (PI3K inhibitors) underperform: the drug spikes blood glucose, the body answers with a surge of insulin, and that insulin reaches around and re-activates PI3K in the tumour. The fix, in mice, was a ketogenic diet to blunt the insulin spike — which made the drugs markedly more effective.[3] The tumour's escape route was insulin; lowering insulin closed it. As on-thesis as science gets — stated, carefully, as adjunct research with oncologists, not a diet that treats cancer alone.
2000–2024 · the vindication

When a broken Krebs enzyme really does cause cancer.

Here's the twist that would have delighted Warburg. For a specific set of cancers, his strong claim — that a broken metabolic enzyme drives the disease — turned out to be literally true. Mutations in actual Krebs-cycle and mitochondrial enzymes cause cancer: SDH (succinate dehydrogenase, part of the respiratory chain) in hereditary paraganglioma,[4] fumarate hydratase in a kidney cancer, and IDH in leukaemia and brain tumours.

The IDH story went all the way to the pharmacy. Mutant IDH churns out an abnormal metabolite that blocks cells from maturing — and drugs that switch the rogue enzyme off (ivosidenib for IDH1, enasidenib for IDH2, brain-penetrant vorasidenib for IDH-mutant gliomas) let the trapped cells finish growing up.[5] They treat the metabolic lesion — not by poisoning the cell, but by fixing its chemistry. They came from Agios, a company Cantley helped found on the premise that cancer metabolism is druggable. And in 2019 the Nobel went to Kaelin, Semenza and Ratcliffe for how cells sense oxygen: Warburg's themes, a century on, still collecting Nobels.

Where this leaves you

Heresy to prescription pad.

The Warburg lineage is a lesson in how science actually works — not a straight line, but a spiral. Warburg got the machinery of respiration exactly right and won the Nobel for it. He overreached on cancer, and the field was right to correct him. But the instinct under the overreach — that a tumour's handling of fuel is central, not incidental — was prophetic, and the correction refined it rather than burying it.

Metabolism is a central, drug-targetable feature of cancer that interacts tightly with genetics — not the single cause he claimed, but nothing like the sideshow his critics claimed either.

Right about the machinery, too strong about the cause, prophetic about metabolism mattering at all.

The story behind the terrain. Back to: Cancer & the Fire · and the whole: The Invisible Fire.

Verified references

[1] Warburg O (1956). On the origin of cancer cells. Science 123(3191):309-314. PMID 13298683. Read →

[2] Vander Heiden MG, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029-1033. PMID 19460998. Read →

[3] Hopkins BD, Pauli C, Du X, et al. (2018). Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560(7719):499-503. PMID 30051890. Read →

[4] Baysal BE, Ferrell RE, Willett-Brozick JE, et al. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287(5454):848-851. PMID 10657297. Read →

[5] DiNardo CD, Stein EM, de Botton S, et al. (2018). Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 378(25):2386-2398. PMID 29860938. Read →